The burden of isoniazid-resistant tuberculosis (Hr-TB) and multidrug- and/or rifampicin
mono-resistant tuberculosis (MDR/RR-TB) is increasing worldwide, and the high TB burden
countries are the worst affected1
2. Ideally, early identification and treatment of Hr-TB is important to prevent progression
to MDR-TB, poly-drug resistant (DR) TB, extensively drug-resistant (XDR) TB and worse
treatment outcomes3. The term XDR-TB will likely need to be re-defined in view of
the injectables no longer being recommended as the frontline treatment for MDR-TB4.
Although both solid and liquid culture methods are invaluable tools for the laboratory
diagnosis of DR-TB, they are time-consuming to detect drug resistance and drug susceptibility.
Rapid molecular methods such as GeneXpert and/or first-and second-line line probe
assay (SL-LPA), when performed in tandem, can provide valuable information about early
diagnosis and drug susceptibility testing (DST)-guided treatment of DR-TB3
5. In this context, it is also essential to offer universal DST to all TB patients
at baseline and during follow up. For this, national TB control programmes must have
adequate laboratory infrastructure, trained healthcare workers and quality-assured
laboratory DST reporting for both first-and second-line drugs to facilitate DST-guided
treatment. As annual national DR-TB surveys are time-consuming and expensive, national
surveys should be carried out periodically to ascertain trends in DR-TB.
The WHO recommends, albeit based on weak evidence, substitution of isoniazid with
levofloxacin (Lfx) for the treatment of laboratory-confirmed Hr-TB (rifampicin-susceptible)
and use of the drug regimen consisting of ERZ (ethambutol, rifampicin, pyrazinamide)-Lfx
for a duration of six months without a split of intensive and continuation phases6.
It further advises against the addition of streptomycin or any other injectable agent
in the regimen. Treatment may be extended up to nine months depending upon the clinical,
radiological and microbiological response and especially in extrapulmonary TB involving
bone, brain/meninges and/or miliary TB. Substitution of a drug in case of additional
drug resistance or intolerance can be effected by, in order of preference with linezolid
(Lzd), clofazimine (Cfz) or cycloserine (Cs). High-dose isoniazid (15-20 mg/kg/day)
may not be useful in Indian patients with Hr-TB since the katG gene mutation conferring
high-dose INH resistance is present in >90 per cent of isolates7. According to the
first National Anti-Tuberculosis Drug Resistance Survey (NDRS) in India, resistance
to any fluoroquinolone (FQ) was found in about eight per cent of Hr-TB and resistance
to Lzd was uncommon in MDR/RR-TB and even less in H mono/poly-DR-TB (personal communication
with RNTCP). Cultures should be done at the end of 2-3 months and thereafter as expropriate8.
Although Mfx may arguably be more potent than Lfx9, the main advantage of the latter
is less QTcF prolongation, which has obvious advantages when combined with other QTcF-prolonging
agents, such as bedaquiline (Bdq) and Cfz in regimen. Peak plasma concentration and
exposure to Mfx significantly decreases with concurrent administration of rifampicin9;
this is another advantage of using Lfx, which does not require dosage adjustment.
Unlike Mfx, Lfx requires dose modification in patients with advanced stages of chronic
kidney disease (CKD).
The recently published consolidated guidelines on MDR/RR-TB9 are based on evidence
synthesized from a recently completed Phase III clinical trial of delamanid (Dlm)10
11, an individual patient data meta-analysis (IPD-MA) of longer12 and 9-12-month shorter
MDR-TB regimens13
14 and efficacy and pharmacokinetic data from Dlm and Bdq-related clinical trials15.
There are no changes in the timing of antiretroviral drugs administration in people
living with HIV (PLHIV) with MDR/RR-TB, use of surgery and models of MDR-TB care (ambulatory
care/hospitalization)16.
A new feature in the guidelines is that the second-line anti-TB drugs used for designing
individualized MDR-TB regimens have been re-grouped into A, B and C and the drug ranking
is based on their estimated efficacy profiles9. The group A drugs include FQ, Lfx
or Mfx; Bdq and Lzd; group B includes Cfz and Cs or terizidone and group C contains
ethambutol (E), Dlm, pyrazinamide, imipenem-cilastatin (Imp-Cln) or meropenem (Mpm),
amikacin (Am) or streptomycin (S), ethionamide (Eto), or prothionamide and p-aminosalicylic
acid (PAS). Lack of efficacy in the Dlm phase III study has resulted in its classification
as a group C drug though this was based on a six-month culture conversion outcome10
11.
While designing the individualized longer (18-20 month) MDR-TB regimen, a strong recommendation
has been made to include all three drugs from group A, and to complete the regimen,
the fourth drug should be from group B (and if it is not possible, then the fourth
drug may be selected from the group C). A fully oral long-term regimen is the preferred
option and the injectable agents, kanamycin and capreomycin, are no longer recommended
because these were associated with higher treatment failure, relapse rates and mortality
and toxicity9. The long-term Bdq-containing drug regimen should have at least four
drugs for initial six months and subsequently three drugs to be continued for rest
of the duration of treatment. Although the optimal number of drugs for the regimen
is uncertain, we recommend a minimum of four but ideally five likely effective drugs12.
The individualized, longer MDR-TB regimen is to be administered for a total duration
of 18-20 months, and the duration is primarily based on patient's response to treatment
or 15-17 months after culture conversion. However, the optimal treatment duration
remains unclear. The WHO recommendations have emphasized monthly sputum cultures along
with smear microscopy9.
Pyrazinamide is to be used for MDR/RR-TB only when DST reveals susceptibility9 (though
this is not readily available and is technically challenging). Every dose of Imp-Cln
or Mpm is administered with clavulanic acid (available only as amoxicillin clavulanic
acid) and this combination is counted as single drug. In selected patients where a
regimen cannot be constructed because of resistance profiles or drug-specific toxicity,
Am or streptomycin is to be used only in patients >18 yr of age, and when high-quality
audiometry monitoring for hearing loss is available. Am is to be substituted with
streptomycin only if it is not available or some other contraindication exists, and
when DST confirms susceptibility to streptomycin (phenotypic DST is required for streptomycin
as molecular DST with SL-LPA does not detect it)9.
It should be noted that thiacetazone, gatifloxacin and high-dose isoniazid were not
included in the IPD-MA for longer regimens because of an inadequate number of patients12
(both gatifloxacin and thioacetazone are no longer available). Evidence on the safety
and efficacy of the following drugs was insufficient for review: use of Bdq beyond
six months and below the age of six years and Dlm use beyond six months and below
the age of three years; concomitant use of Bdq and Dlm. It was observed that the use
of Lzd for at least six months showed increased efficacy and using it for the entire
duration would likely be better12; however, one needs to balance this against the
high rates of drug toxicity with prolonged use.
The new WHO guidelines has left open the option of using the longer 18-20 month group
A-based regimen or the standardized shorter MDR-TB regimen containing an injectable
which is given for 9-11 months9. Which regimen should preferably be used? In the recently
published STREAM trial, the shorter injectable containing 9-11 month regimen was found
to be non-inferior to the conventional 18-20 month older WHO regimen (also contained
an injectable)14. However, bacteriologic outcomes were worse with the shorter regimen
and there was a trend to worse outcomes in HIV-infected persons in both arms. Given
these considerations, the toxicity and tolerability profiles (including months of
painful injections), our personal recommendation is that the longer pan-oral regimen
is preferable and that the standardized shorter MDR-TB regimen containing an injectable
should only be used as an exception (for example, if drugs are not readily accessible)
and provided (i) there is no proven or likely resistance to any component of the regimen
(except isoniazid), (ii) there is access to baseline and longitudinal monitoring for
hearing loss, (iii) FQ and second line injectable drug (SLID) resistance has been
excluded, and (iv) patients have been counselled about the risks of this regimen and
agree to receive it. There should be clear plans within the programme or provider
setting to transition to an all-oral group A-based regimen because the shorter WHO
injectable-based regimen is likely to be an inferior one from an efficacy and mortality
point of view (though there are no head-to-head trials yet), and Am is toxic and associated
with chronic painful injections driving poor adherence.
Active TB drug-safety monitoring and management (aDSM)17 should be an integral part
of MDR-TB management as several drugs have additive toxicities. Bdq, Dlm, FQ (Mfx>Lfx)
and Cfz have the potential to prolong QTcF. It is advised that deficiencies of potassium,
calcium and magnesium should be corrected first, and if QTcF >500 ms persists, then
the likely offending drug(s) should be stopped. Similarly, several drugs (Lzd, ethambutol
and INH) in the regimen, when given in combination, can produce optic neuropathy17.
Lzd is a potent drug with potential toxicity when used on long-term basis in MDR-TB
regimens18. Haematological toxicity occurs early, whereas peripheral and optic neuropathy
occurs late18. Lactic acidosis is a rare complication. Pyridoxine (100 mg daily) can
be administered to decrease the risk of haematological toxicity. Lzd is very rarely
associated with serotonin syndrome when administered with selective serotonin re-uptake
inhibitors and other medicines known to increase serotonin concentration in the central
nervous system19
20. In this specific context, patients should be instructed to avoid foods and liquids
rich in tyramine concentration.
Proposed Indian recommendations for the fully oral longer regimen include five drugs
in the intensive phase and four drugs in the continuation phase [Bdq(6 months) Lfx
Lzd Cfz Cs]. After the drug procurement, implementation will start in a phased manner.
If resistance to the FQ class is detected on the SL-LPA, then preferably two drugs
(or at least one) from group C, e.g. Dlm and/or PAS, should be added to the regimen.
In some cases high-dose Mfx (Mfxh) could be useful provided there is no resistance
to Mfxh (1.0 μg)21 on LC-DST17 [though specific mutations of the SL-LPA, i.e. A90V,
S91P, D94A (gyrA) suggest low level Mfx resistance in many settings]. Baseline SL-LPA
should be performed for all patients with MDR/RR-TB to clarify whether there is additional
FQ class resistance, which varies from 10 to 40 per cent in India (personal communication
with RNTCP). A fully oral Bdq-containing shorter regimen remains a good prospect for
the treatment of MDR-TB in future.